Residency · Residency · Medical Genetics Genomics

Cascade Testing and Family Communication

Introduction

Cascade testing is the systematic process of offering genetic testing to at-risk biological relatives after a pathogenic variant has been identified in a proband. It is one of the most cost-effective strategies in genomic medicine, enabling presymptomatic identification of individuals at risk for actionable genetic conditions. However, its success depends entirely on effective family communication, which presents significant practical, psychological, and ethical challenges.

Principles of Cascade Testing

Definition and Scope

Cascade testing involves targeted testing of relatives for a known familial pathogenic variant. It begins with first-degree relatives (parents, siblings, children) and expands to second- and third-degree relatives based on results. It is applicable across clinical genetics: hereditary cancer syndromes, cardiac genetic conditions, familial hypercholesterolemia, hereditary hemochromatosis, and many others. Each positive result identifies a new set of at-risk relatives, creating the cascade effect.

Clinical Impact

Cascade testing enables presymptomatic identification and initiation of risk-reducing surveillance or interventions. Relatives who test negative for the familial variant can be released from enhanced surveillance, reducing unnecessary screening and anxiety. For familial hypercholesterolemia, cascade testing is the most effective identification strategy and is endorsed by WHO, ESC, and AHA. For hereditary breast/ovarian cancer (BRCA1/2), identification of carriers enables risk-reducing surgery, chemoprevention, and enhanced screening. For Lynch syndrome, cascade testing enables colonoscopy surveillance that reduces colorectal cancer mortality by more than 50%.

Family Communication Challenges

Barriers to Information Sharing

Probands may feel emotional burden and guilt about transmitting a variant to children or siblings. Family dynamics including estranged relationships, conflict, geographic distance, or loss of contact impede communication. Misunderstanding of risk means probands may not fully grasp which relatives are at risk or the implications. The desire to protect leads some to withhold information to avoid causing worry, particularly to elderly parents or young adult children. Stigma and discrimination concerns arise from fear of insurance or employment discrimination despite legal protections. Cultural factors in some communities discourage discussion of health or genetic conditions within families.

Facilitating Communication

Pre-test counseling should include discussion of the obligation and plan for family notification. Family letters (template letters that probands can share with relatives explaining the finding, its significance, and how to pursue testing) are essential tools. Genetic counselors can assist with communication by helping draft personalized messages or facilitating family meetings. Visual aids and educational materials in multiple languages and at appropriate literacy levels support understanding. Identifying a family champion who can facilitate information dissemination within the family improves reach. Follow-up appointments assess progress in family notification and address obstacles.

Models of Cascade Testing Programs

Proband-Mediated (Traditional Model)

In this model, the proband is responsible for informing at-risk relatives while the clinical team provides tools and support but does not contact relatives directly. Its advantages include respecting proband autonomy and family privacy. Its limitations include often low uptake (20-40%) due to communication barriers and complete reliance on proband initiative.

Direct Contact Model

With proband consent, the clinical team contacts at-risk relatives directly by letter or phone. This model has been implemented successfully in programs for familial hypercholesterolemia in the Netherlands and Australia. Significantly higher uptake (above 80% in some programs) is achieved compared to proband-mediated approaches. It requires robust consent processes and infrastructure.

Hybrid Approaches

The proband is given the first opportunity to inform relatives within a defined timeframe. If relatives remain uninformed, the clinical team follows up with proband permission. This balances autonomy with public health responsibility.

Condition-Specific Considerations

Hereditary Cancer Syndromes

For BRCA1/2, cascade testing identifies carriers who benefit from enhanced screening (breast MRI), risk-reducing surgery (mastectomy, salpingo-oophorectomy), and chemoprevention. For Lynch syndrome, relatives benefit from colonoscopy starting at age 20-25 and aspirin chemoprevention. For Li-Fraumeni syndrome, whole-body MRI surveillance is recommended, though the high psychological burden requires careful counseling.

Cardiac Genetics

For hypertrophic cardiomyopathy, cascade genetic testing guides clinical screening intervals, and variant-negative relatives can avoid serial echocardiography. For long QT syndrome, genotype-specific management includes beta-blockers, activity restriction, and ICD considerations. For familial hypercholesterolemia, statin initiation can begin in childhood for identified carriers.

Pediatric Considerations

Testing minors for adult-onset conditions is generally deferred unless the condition has childhood-onset implications or actionable interventions exist in childhood. Adolescents approaching adulthood should be offered age-appropriate counseling about cascade testing. Parental testing decisions for children must balance the child's future autonomy with potential health benefits.

Ethical and Legal Framework

Duty to Warn vs. Patient Confidentiality

Tension exists between the proband's right to privacy and the potential benefit to at-risk relatives. The landmark ABC v St George's Healthcare NHS Trust (2020) case in the UK established that clinicians may have a duty of care to at-risk relatives in certain circumstances. Most jurisdictions prioritize patient confidentiality but allow exceptions when the condition is serious and actionable, the risk to the relative is high, the proband has been counseled and still refuses to inform, and the relative can be identified and contacted.

Professional Guidelines

ACMG encourages clinicians to facilitate family communication but generally supports proband-mediated disclosure. ESHG (European Society of Human Genetics) recognizes circumstances where direct contact may be ethically justified. The genetic counselor code of ethics prioritizes patient autonomy while acknowledging responsibilities to family members.

Measuring Cascade Testing Effectiveness

Metrics include uptake rate (proportion of at-risk relatives who undergo testing), time to testing (interval between proband diagnosis and relative testing), clinical outcomes (changes in management, early disease detection, risk reduction achieved), and psychological outcomes (anxiety, quality of life, family relationships after cascade testing). Current estimates suggest that for every proband identified with a hereditary cancer syndrome, an average of 2-3 additional carriers can be found through effective cascade testing.

Clinical Pearls

Cascade testing is among the most cost-effective interventions in genomic medicine but remains significantly underutilized due to barriers in family communication. Pre-test counseling should proactively address the plan for family notification; providing family letters and clear instructions for relatives dramatically improves uptake. Direct contact models achieve substantially higher cascade testing uptake than proband-mediated approaches and should be considered where infrastructure and consent allow. The ethical tension between proband confidentiality and the welfare of at-risk relatives requires careful navigation with institutional ethics support when needed.

References

1. Knowles JW, Rader DJ, Khoury MJ. Cascade screening for familial hypercholesterolemia and the use of genetic testing. JAMA. 2017;318(4):381-382.
2. Suthers GK, Armstrong J, McCormack J, Trott D. Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorder. Journal of Medical Genetics. 2006;43(8):665-670.
3. Frey MK, Ahsan MD, Engel SM, et al. Cascade testing for hereditary cancer syndromes: should we move toward a population-based approach? Journal of Clinical Oncology. 2023;41(6):1130-1138.
4. Watts GF, Sullivan DR, Poplawski N, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atherosclerosis Supplements. 2011;12(2):221-263.

Read this lecture as Markdown